On June 15th, Boston-based myBiometry was the recipient of MeHI's $10,000 cash award for innovation at Boston Scientific's Connected Patient Challenge VII, administered by M2D2. myBiometry is a platform designed to remotely monitor and manage patients with asthma using software and biomarker data generated from proprietary sensors.
Their solution is designed to stop asthma attacks before they happen by measuring biomarkers of airway inflammation, specifically fractional exhaled nitric oxide in a patient’s breath. Nitric oxide levels can indicate a potential asthma attack long before any outward symptoms arise. Checking those levels daily helps to determine the risk of attack, monitor adherence and efficacy of medication, and track exposure to environmental triggers. Patients can then make lifestyle changes to lower their risk of an attack.
The aim is to offer personalized, predictive risk models for each patient, so patients can take action to ultimately improve asthma control. While their initial focus is asthma, the company hopes to expand to support other chronic health conditions in the future. Learn more about myBiometry here.
July 20, 2023
Source:
Massachusetts eHealth Institute (MeHI)